Summary
Differentials
Uncommon
- Carcinoid tumor
- Lymphoma
- Sarcoidosis
- Rheumatoid arthritis
- Granulomatosis with polyangiitis (formerly known as Wegener granulomatosis)
- Arteriovenous malformation
- Intrapulmonary lymph node
- Pulmonary amyloidosis
- Mucoid impaction
Contributors
Authors
Erik E. Folch, MD, MSc

Chief, Complex Chest Disease Center
Co-director, Interventional Pulmonology Massachusetts General Hospital
Harvard Medical School
Boston
MA
Disclosures
EEF is the global principal investigator for the NAVIGATE trial, sponsored by Medtronic. He has also served as scientific consultant for Boston Scientific in the development of advanced bronchoscopic techniques.
Peter J. Mazzone, MD, MPH, FCCP

Director of Lung Cancer Program
Director of Lung Cancer Screening Program
Director of Education
Respiratory Institute
Cleveland Clinic
Cleveland
OH
Disclosures
PJM has been paid to participate in clinical advisory board meetings for Oncimmune, InDi, Nucleix, Grail, and Oncocytelooking, all companies interested in developing molecular biomarkers for the evaluation of lung nodules/ lung cancer; he does not have a contractual agreement to disseminate product information for any of these companies. PJM has participated in research supported by InDi Veracyte, that was paid to his institution. He has also participated in research with in-kind support from Oncimmune and 20/20 Genesystems.
Peer reviewers
Pallav L. Shah, MD, MBBS, FRCP
Consultant Physician
Royal Brompton Hospital
Chelsea & Westminster Hospital
London
UK
Disclosures
PLS declares that he has no competing interests.
Sangeeta M. Bhorade, MD
Associate Professor of Medicine
Medical Director
Lung Transplant Program
University of Chicago Hospitals
Chicago
IL
Disclosures
SMB declares that she has no competing interests.
Patient leaflets
Lung cancer (non-small-cell)
More Patient leafletsLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer